Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgery
Erschienen in: Indian Journal of Surgery 4/2022

06.09.2021 | Review Article

Recent Advances and Concepts in SLNB (Sentinel Lymph Node Biopsy) and Management of SLNB Positive Axilla in Carcinoma Breast

verfasst von: S. P. Somashekhar, K. R. Ashwin, Rohit Kumar C

Erschienen in: Indian Journal of Surgery | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is one of the three most common cancers occurring worldwide. In 2018, one in four newly detected cancer in women was breast cancer in India. Breast cancer treatment approaches have changed from “maximum tolerable” to “minimum effective” with the same cure rates and cosmesis but better quality of life (QoL). However, the management of the axilla has been a debatable topic since many decades. For the proper management of breast cancer, it is essential to differentiate clinically node-positive or clinically node-negative patients but having a positive sentinel lymph node (SLN). Axillary staging is one of the most important prognostic variables in breast cancer treatment. Sentinel lymph node biopsy (SLNB) may spare many patients the need for axillary lymph node dissection (ALND) as well as the morbidities associated with ALND. In this review, we have discussed the observations from various trials and guidelines recommendations on the need or omission of ALND in patients with breast cancer undergoing SLNB. The various tracer used for identification of SLN and the best combination available for staging the axilla with high accuracy and low risk of false negativity has been assessed. The timing and accuracy of SLNB in patients who are receiving neoadjuvant chemotherapy (NACT) for breast cancer have also been discussed. The impact of ALND on locoregional recurrence (LR), overall survival (OS), and disease-free survival (DFS) outcomes in SLNs positive patients has been evaluated. We have proposed a treatment algorithm to follow, in addition to the local/regional guideline recommendations, before planning the treatment strategy for breast cancer patients.
Literatur
1.
2.
3.
4.
Veronesi U, Stafyla V, Luini A, Veronesi P (2012) Breast cancer: from “maximum tolerable” to “minimum effective” treatment. Front Oncol 2:125PubMedPubMedCentralCrossRef
5.
Kaviani A, Sodagari N, Sheikhbahaei S, Eslami V, Hafezi-Nejad N, Safavi A, Noparast M, Fitoussi A (2013) From radical mastectomy to breast-conserving therapy and oncoplastic breast surgery: a narrative review comparing oncological result, cosmetic outcome, quality of life, and health economy. Int Sch Res Notices 2013:742462
6.
Yan M, Abdi MA, Falkson C (2018) Axillary management in breast cancer patients: a comprehensive review of the key trials. Clin Breast Cancer 18(6):e1251–e1259PubMedCrossRef
7.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310PubMedPubMedCentralCrossRef
8.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth W, Blumencranz W, Leitch M, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575PubMedPubMedCentralCrossRef
9.
Sakorafas GH, Tsiotou AG, Balsiger BM (2000) Axillary lymph node dissection in breast cancer: current status and controversies, alternative strategies and future perspectives. Acta Oncol 39(4):455–466PubMedCrossRef
10.
Konkin DE, Tyldesley S, Kennecke H, Speers CH, Olivotto IA, Davis N (2006) Management and outcomes of isolated axillary node recurrence in breast cancer. Arch Surg 141(9):867–874PubMedCrossRef
11.
Fisher CS, Margenthaler JA, Hunt KK, Schwartz T (2020) The landmark series: axillary management in breast cancer. Ann Surg Oncol 27(3):724–729PubMedCrossRef
12.
Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 6:109–116PubMedCrossRef
13.
Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(5):561–564PubMedCrossRef
14.
Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2880PubMedCrossRef
15.
16.
Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB (2006) Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 93:129–132PubMedCrossRef
17.
Attene F, Paliogiannis P, Scognamillo F, Trignano E, Pala C, Trignano M (2012) Axillary lymph node dissection in patients with breast cancer and sentinel lymph node micro metastasis or isolated tumor cells: is it necessary? Tumori 98(3):320–323PubMedCrossRef
18.
Smidt ML, Janssen CM, Kuster DM, Bruggink ED, Strobbe LJ (2005) Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12(1):29–33PubMedCrossRef
19.
Axelsson CK, Mouridsen HT, Zedeler K (1992) Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 28A:1415–1418PubMedCrossRef
20.
Girgin S, Soran A, Güler N, Dinçer M, Demir G (2014) Is completion axillary dissection necessary for this patient? J Breast Health 10(3):184–188PubMedPubMedCentralCrossRef
21.
Bevilacqua JL, Kattan MW, Fey JV, Cody HS III, Borgen PI, Van Zee KJ (2007) Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 25(24):3670–3679PubMedCrossRef
22.
Kissin MW, Price AB, Thompson EM, Slavin G, Kark AE (1982) The inadequacy of axillary sampling in breast cancer. Lancet 319(8283):1210–1212CrossRef
23.
Abass MO, Gismalla MD, Alsheikh AA, Elhassan MM (2018) Axillary lymph node dissection for breast cancer: Efficacy and complication in developing countries. J Glob Oncol 4:1–8PubMed
24.
Novoa AG, Nebril BA (2017) Axillary treatment in breast cancer surgery: systematic review of its impact on survival. Cirugía Española (English Edition) 95(9):503–512CrossRef
25.
Cataliotti L, Distante V, Rontini M, Ponzano C, Manetti A, Falli F (1995) Role of axillary dissection in breast carcinoma. Chir Ital 47(4):23–31PubMed
26.
Jeong EH, Choi EJ, Choi H, Park EH, Song JS (2019) Prediction of axillary lymph node metastasis in early breast cancer using dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging. IMRI 23(2):125–135
27.
28.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ (2014) Risk of positive nonsentinel nodes in women with 1–2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J 20(4):358–363PubMedCrossRef
29.
Katz A, Smith BL, Golshan M, Niemierko A, Kobayashi W, Raad RA, Kelada A, Rizk L, Wong JS, Bellon JR, Gadd M (2008) Nomogram for the prediction of having four or more involved nodes for sentinel lymph node–positive breast cancer. J Clin Oncol 26:2093–2098PubMedCrossRef
30.
Chagpar AB, Scoggins CR, Martin RC, Cook EF, McCurry T, Mizuguchi N, Paris KJ, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ (2007) Predicting patients at low probability of requiring postmastectomy radiation therapy. Ann Surg Oncol 14(2):670–677PubMedCrossRef
31.
Hussain T, Kneeshaw PJ (2014) Axillary lymph node clearance in patients with positive sentinel lymph node biopsy. Ann R Coll Surg Engl 96(3):199–201PubMedPubMedCentralCrossRef
32.
Chao C, Wong SL, Woo C, Edwards MJ, Tuttle T, Noyes RD, Carlson DJ, Turk P, Simpson D, McMasters KM (2001) Reliable lymphatic drainage to axillary sentinel lymph nodes regardless of tumor location within the breast. Am J Surg 182(4):307–311PubMedCrossRef
33.
Mack M, Chetlen A, Liao J (2015) Incidental internal mammary lymph nodes visualized on screening breast MRI. AJR Am J Roentgenol 205(1):209–214PubMedCrossRef
34.
Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR (2008) Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review. J Clin Oncol 26(30):4981–4989PubMedCrossRef
35.
Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, Cox CE, Reintgen DS (2001) Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 136(6):688–692PubMedCrossRef
36.
37.
Zahoor S, Haji A, Battoo A, Qurieshi M, Mir W, Shah M (2017) Sentinel lymph node biopsy in breast cancer: a clinical review and update. J Breast Cancer 20(3):217–227PubMedPubMedCentralCrossRef
38.
Roh JL, Koch WM (2010) Role of sentinel lymph node biopsy in thyroid cancer. Expert Rev Anticancer Ther 10(9):1429–1437PubMedCrossRef
39.
Krynyckyi BR, Shafir MK, Kim SC, Kim DW, Travis A, Moadel RM, Kim CK (2005) Lymphoscintigraphy and triangulated body marking for morbidity reduction during sentinel node biopsy in breast cancer. Int Semin Surg Oncol 2:25PubMedPubMedCentralCrossRef
40.
Sappey PC (1885) Description et iconographie des vaisseaux lymphatiques, considérés chez l’homme et les vertébrés. Paris, Delahaye 48:136
41.
Pilewskie ML, Morrow M (2014) Management of the Clinically Node-Negative Axilla: What Have We Learned From the Clinical Trials? Oncology. 28(5).
42.
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, De Cicco C, Geraghty JG, Luini A, Sacchini V (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349(9069):1864–1867PubMedCrossRef
43.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220(3):391–398PubMedPubMedCentralCrossRef
44.
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF (2000) Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 124(7):966–978PubMedCrossRef
45.
Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703–7720PubMedCrossRef
46.
Min JW, Cho J (2021) Minimal Invasive and Individualizing Management of the Axillary Nodes. Adv Exp Med Biol 1187:591–599PubMedCrossRef
47.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8):567–575PubMedCrossRef
48.
49.
Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B (2003) The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 98(7):1362–1368.
50.
Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, Campana F, Fourquet A (2004) Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 22(1):97–101PubMedCrossRef
51.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933PubMedPubMedCentralCrossRef
52.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609PubMedCrossRef
53.
Van der Ploeg IM, Nieweg OE, Van Rijk MC, Olmos RV, Kroon BB (2008) Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 34(12):1277–1284PubMedCrossRef
54.
Blessing WD, Stolier AJ, Teng SC, Bolton JS, Fuhrman GM (2002) A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg 184(4):341–345PubMedCrossRef
55.
Aihara T, Takatsuka Y (2003) Dye-guided sentinel node biopsy revisited; validation and observational study from a single institute. Breast Cancer 10(3):254–259PubMedCrossRef
56.
Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M (2003) Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol 10(3):242–247PubMedCrossRef
57.
Watanabe T, Kimijima I, Ohtake T, Tsuchiya A, Shishido F, Takenoshita S (2001) Sentinel node biopsy with technetium-99m colloidal rhenium sulphide in patients with breast cancer. Br J Surg 88(5):704–707PubMedCrossRef
58.
Offodile R, Hoh C, Barsky SH, Nelson SD, Elashoff R, Eilber FR, Economou JS, Nguyen M (1998) Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 82(9):1704–1708PubMedCrossRef
59.
Hodgson N, Zabel P, Mattar AG, Engel CJ, Girvan D, Holliday R (2001) A new radiocolloid for sentinel node detection in breast cancer. Ann Surg Oncol 8(2):133–137PubMedCrossRef
60.
Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, Koyama H (2001) Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol 76(2):95–99PubMedCrossRef
61.
Cserni G, Rajtár M, Boross G, Sinkó M, Svébis M, Baitás B (2002) Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer. World J Surg 26(5):592–597PubMedCrossRef
62.
McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A, Cerrito PB (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18(13):2560–2566PubMedCrossRef
63.
Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, Ku NN, Lyman GH, Berman C, Haddad F, Reintgen DS (1998) Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227(5):645–651; discussion 651–653.
64.
Paganelli G, De Cicco C, Cremonesi M et al (1998) Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med 42:49–53PubMed
65.
Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C (1999) Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 91:368–373PubMedCrossRef
66.
Zervos EE, Burak WE (2000) Lymphatic mapping for breast cancer: experience at The Ohio State University. Breast Cancer 7(3):195–200PubMedCrossRef
67.
Villa G, Gipponi M, Buffoni F, Vecchio C, Bianchi P, Agnese G, Di Somma C, Catturich A, Rosato F, Tomei D, Nicolò G (2000) Localization of the sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye and intraoperative gamma probe. Tumori 86(4):297–299PubMedCrossRef
68.
Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H, Ohta M, Kurosumi M, Tsugawa K (2000) A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat 63(1):31–40PubMedCrossRef
69.
Yu JC, Hsu GC, Liu YC, Sheu LF, Li SH, Chao TY (2002) Sentinel node biopsy in early breast cancer in Taiwan. World J Surg 26(11):1365–1369PubMedCrossRef
70.
Nano MT, Kollias J, Farshid G, Gill PG, Bochner M (2002) Clinical impact of false-negative sentinel node biopsy in primary breast cancer. Br J Surg 89(11):1430–1434PubMedCrossRef
71.
Yong WS, Wong CY, Lee JS, Soo KC, Tan PH, Goh AS (2003) Single institution’s initial experience with sentinel lymph node biopsy in breast cancer patients. ANZ J Surg 73(6):416–421PubMedCrossRef
72.
Fortunato L, Farina M, Alessi G, Amini M, Andrich R, Costarelli L, Dell’Osso A, Piro FR, Domini P, Vitelli CE (2003) Sentinel lymph node in breast cancer: experience of 4 years. Chir Ital 55(5):669–680PubMed
73.
Bobin JY, Spirito C, Isaac S, Zinzindohoue C, Joualee A, Khaled M, Perrin-Fayolle O (2000) Lymph node mapping and axillary sentinel lymph node biopsy in 243 invasive breast cancers with no palpable nodes. The south Lyon hospital center experience. Ann Chir 125(9):861–870.
74.
Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S (1998) The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 339:941–946PubMedCrossRef
75.
Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, Ng PC, Edwards MS, Halliday BE, Henry CA, Sommers LM (2001) Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 233:51–59PubMedPubMedCentralCrossRef
76.
Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M, Reintgen D (2002) Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255PubMedCrossRef
77.
Somashekhar SP, Shabber SZ, Venkatesh KU, Venkatachala K, Thirumalai MV (2008) Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid—a single institution Indian experience. Indian J Surg 70(3):111–119PubMedPubMedCentralCrossRef
78.
D’Eredita G, Ferrarese F, Cecere V, Massa ST, de Carne F, Fabiano G (2003) Subareolar injection may be more accurate than other techniques for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 10(8):942–947PubMedCrossRef
79.
Pelosi E, Bellò M, Giors M, Ala A, Giani R, Bussone R, Bisi G (2004) Sentinel lymph node detection in patients with early-stage breast cancer: comparison of periareolar and subdermal/peritumoral injection techniques. J Nucl Med 45(2):220–225PubMed
80.
Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S (1999) Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 229(6):860–864PubMedPubMedCentralCrossRef
81.
Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, Bedrosian I, Fraker DL, Bauer TL, Czerniecki BJ (2002) Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 9(2):169–176PubMedCrossRef
82.
Pesek S, Ashikaga T, Krag LE, Krag D (2012) The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg 36(9):2239–2251PubMedPubMedCentralCrossRef
83.
East JM, Valentine CS, Kanchev E, Blake GO (2009) Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg 9(1):1–8CrossRef
84.
Somashekhar SP, Kumar CR, Ashwin KR, Zaveri SS, Jampani A, Ramya Y, Parameswaran R, Rakshit S (2020) Can low-cost indo cyanine green florescence technique for sentinel lymph node biopsy replace dual dye (radio-colloid and blue dye) technique in early breast cancer: a prospective two-arm comparative study. Clin Breast Cancer 20(5):e576–e583PubMedCrossRef
85.
Klausen TL, Chakera AH, Friis E, Rank F, Hesse B, Holm S (2005) Radiation doses to staff involved in sentinel node operations for breast cancer. Clin Physiol Funct Imaging 25(4):196–202PubMedCrossRef
86.
Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW (2005) Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg 92(12):1494–1497PubMedCrossRef
87.
Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schröder CP, de Vries EG, van Dam GM (2018) Evolution in sentinel lymph node biopsy in breast cancer. Crit Rev Oncol Hematol 123:83–94PubMedCrossRef
88.
Somashekhar SP, Kumar CR, Ashwin KR, Rakshith S, Jampani A, Ramya Y (2019) Indocyanine Green (ICG) fluorescence imaging in sentinel lymph node biopsy (SLNB) for early breast cancer: first Indian experience. Indian J Gyne Oncol 17(2):1–7
89.
Kedrzycki MS, Leiloglou M, Ashrafian H, Jiwa N, Thiruchelvam PT, Elson DS, Leff DR (2021) Meta-analysis comparing fluorescence imaging with radioisotope and blue dye-guided sentinel node identification for breast cancer surgery. Ann Surg Oncol 28(7):3738–3748PubMedCrossRef
90.
Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP (2010) Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 116(5):1243–1251PubMedCrossRef
91.
Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23(12):2694–2702PubMedCrossRef
92.
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609–618PubMedCrossRef
93.
Fontein DB, van de Water W, Mieog JS, Liefers GJ, van de Velde CJ (2013) Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy–recommendations for clinical guidance. Eur J Surg Oncol 39(5):417–424PubMedCrossRef
94.
Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, Sadetzki S (2008) Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98(6):403–406PubMedCrossRef
95.
Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK (2016) Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy–results from ACOSOG Z1071 (Alliance). Ann Surg 263(4):802–807PubMedCrossRef
96.
Coufal O, Zapletal O, Gabrielová L, Fabian P, Schneiderová M (2018) Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy-a retrospective study. Rozhl Chir 97(12):551–557PubMed
97.
Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, Lubitz J, Hellerhoff K, Ankel C, Graßhoff ST, Deuschle P (2021) A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Annals of Surgery. Abstract doi: https://​doi.​org/​10.​1097/​SLA.​0000000000004572​.
98.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan M, Senn HJ, Winer EP, Gnant M (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol S0923–7534(21)02104–9
99.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRef
100.
Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, Skelly JM, Harlow SP, Weaver DL, Mamounas EP, Costantino JP (2010) Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 102(2):111–118PubMedPubMedCentralCrossRef
101.
Del Bianco P, Zavagno G, Burelli P, Scalcod G, Baruttae L, Carrarof P, Pietrarotag P, Meneghinih G, Morbini T, Tacchettij G, Pecorarok P, Belardinellib V, De Salvo GL, On behalf of GIVOM, (2008) Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol 34(5):508–513PubMedCrossRef
102.
Mansel RE, Goyal A (2004) European studies on breast lymphatic mapping. Semin Oncol 31:304–310PubMedCrossRef
103.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7(12):983–990PubMedCrossRef
104.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micro metastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305PubMedPubMedCentralCrossRef
105.
Julian TB, Anderson ST, Krag DN, Harlow SP, Costantino JP, Weaver TADL, Mamounas EP, Wolmark N (2013) 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol. 31(5):Abstract 1000.
106.
Krag DN, Julian TB, Harlow SP, Weaver DL, Ashikaga T, Bryant J, Single RM, Wolmark N (2004) NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Anna Surg Oncol 11(3):208S-210SCrossRef
107.
Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 252:426–433PubMedCrossRef
108.
Giuliano AE, Hunt K, Ballman KV, Beitsch PD, Whitworth W, Blumencranz W, Leitch M, Saha S, McCall LM, Morrow M (2016) Ten-year survival results of ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node (Alliance). Oral presentation at: 2016 ASCO Annual Meeting; Chicago, IL
109.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ (2015) Regional nodal irradiation in early-stage breast cancer. New Eng J Med 373(4):307–316PubMedCrossRef
110.
Whelan TJ, Olivotto IA, Ackerman I, Chapman JW, Chua B, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Craighead P, Nolan MC, Bowen J, McCready DR, Pritchard KI, Levine MN, Parulekar W (2011) NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 29(18):LBA1003.
111.
Krag DN, Single RM (2003) Breast cancer survival according to number of nodes removed. Ann Surg Oncol 10:1152–1159PubMedCrossRef
112.
113.
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27(18):2946–2953PubMedCrossRef
114.
Somashekhar SP, Naikoo ZA, Zaveri SS, Holla S, Chandra S, Mishra S, Parameswaran RV (2015) Intraoperative frozen section evaluation of sentinel lymph nodes in breast carcinoma: single-institution Indian experience. Indian J Surg 77(Suppl 2):335–340PubMedCrossRef
115.
Jaka RC, Zaveri SS, Somashekhar SP, Sureshchandra, Parameswaran RV (201) Value of frozen section and primary tumor factors in determining sentinel lymph node spread in early breast carcinoma. Indian J Surg Oncol 1(1):27–36.
116.
Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G (2020) Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 21(12):1602–1610PubMedCrossRef
117.
Goyal A, Dodwell DP (2015) POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol 27(12):692–695CrossRef
118.
Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, Wolter K, Hildebrandt G, Gerber B (2017) Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c/iT1–2) in the context of breast conserving therapy: first results following commencement of the Intergroup-Sentinel-Mamma (INSEMA) trial. Geburtshilfe Frauenheilkd 77(2):149–157PubMedPubMedCentralCrossRef
119.
120.
Posther KE, Wilke LG, Giuliano AE (2004) Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol 31:426–436PubMedCrossRef
121.
Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, De Winter K (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373(4):317–327PubMedCrossRef
Metadaten
Titel
Recent Advances and Concepts in SLNB (Sentinel Lymph Node Biopsy) and Management of SLNB Positive Axilla in Carcinoma Breast
verfasst von
S. P. Somashekhar
K. R. Ashwin
Rohit Kumar C
Publikationsdatum
06.09.2021
Verlag
Springer India
Erschienen in
Indian Journal of Surgery / Ausgabe 4/2022
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-021-03100-w

Weitere Artikel der Ausgabe 4/2022

Indian Journal of Surgery 4/2022 Zur Ausgabe

Surgical Techniques and Innovations

Non-randomized Clinical Trial of In-house Silver-Coated Foley’s Catheter Reduces Urinary Tract Infections—a Low-Cost Innovation

Letter to Editor

RAPID EYE: an Aid Memoir for Comprehensive Evaluation of Patient in Post-cardiac Surgery Recovery Unit

Surgical Techniques and Innovations

Laparoscopic Ventral Mesh Rectopexy with Resection of Dolichocolon for Treatment of Obstructed Defecation Syndrome: Technical Report

Review Article

Meta-analysis and Systematic Review in Patients with Locally Advanced Rectal Cancer with Total Mesorectal Excision (TME) Alone and TME Combined with Extended Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiotherapy

Case Report

Duodenal Web in an Adult Patient—a Rare Case

Surgical Techniques and Innovations

Repair of Rectourethral Fistula Using Gracilis Muscle Flap Interposition—a Tertiary Care Center Experience

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise